Table 1 Association between HES9 expression and clinicopathological parameters
From: Podocalyxin is a marker of poor prognosis in colorectal cancer
HES9 expression | |||
|---|---|---|---|
Low | High | ||
n (%) | 723 (94.3) | 44 (5.7) | p-value |
Age, years | |||
<65 | 309 (42.7) | 16 (36.4) | 0.436 |
≥65 | 414 (57.3) | 28 (63.6) | |
Gender | |||
Male | 402 (44.4) | 24 (54.5) | 1.000 |
Female | 321 (55.6) | 20 (45.5) | |
Dukes | |||
A | 109 (15.1) | 2 (4.5) | 0.012 |
B | 259 (35.8) | 13 (29.5) | |
C | 196 (27.1) | 14 (31.8) | |
D | 159 (22.0) | 15 (34.1) | |
Grade (WHO) | |||
1 | 26 (3.6) | 0 (0) | <0.0001 |
2 | 514 (71.5) | 11 (25.0) | |
3 | 161 (22.4) | 25 (56.8) | |
4 | 18 (2.5) | 8 (18.2) | |
Missing | 4 | ||
Location | |||
Colon | 372 (51.5) | 28 (63.6) | 0.123 |
Rectum | 351 (48.5) | 16 (36.3) | |
Side | |||
Right | 189 (26.1) | 23 (52.3) | <0.001 |
Left | 534 (73.9) | 21 (47.7) | |